ALLERGY TREATMENT MARKET ANALYSIS

Allergy Treatment Market, By Type (Eye Allergy, Asthma, Rhinitis, Skin Allergy, Food Allergies, and Others), By Treatment (Anti-allergy Drugs and Immunotherapy), By Distribution Channel (Hospital Pharmacies, Retail Pharmacies, and Online Pharmacies), By Geography (North America, Latin America, Europe, Asia Pacific, Middle East & Africa)

On February 16, 2024, Genentech, Inc., a pharmaceutical company, announced that the U.S. Food and Drug Administration approved Xolair (omalizumab) for the reduction of allergic reactions, including anaphylaxis, that may occur with accidental exposure to one or more foods in adult and pediatric patients aged 1 year and older with IgE-mediated food allergy
On January 24, 2024, Dr Reddy’s Laboratories Ltd., a pharmaceutical company, announced that it had launched allergy medication, Histallay, into the U.K. for general sale
In August 2022, Hikma Pharmaceuticals PLC, a pharmaceutical company, announced the launch of RYALTRIS (olopatadine hydrochloride and mometasone furoate nasal spray) in the U.S. RYALTRIS is approved by the U.S. Food and Drug Administration (FDA) for the treatment of symptoms of seasonal allergic rhinitis (SAR) in adult and pediatric patients 12 years of age and older
In March 2021, ALK-Abelló A/S, a pharmaceutical company, announced its submission of a registration application in China, under National Medical Products Administration (NMPA), a Chinese agency for regulating drugs and medical devices, for its ACARIZAX, a house dust mite (HDM) sublingual allergy immunotherapy (SLIT) tablet